Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
This video features Professor of Oncology Angus Dalgleish sharing crucial information about Low Dose Naltrexone (LDN), an affordable repurposed drug he prescribes to his cancer patients at very low doses. Learn about the mechanisms through which LDN can influence cancer progression, including antagonism of toll-like receptors 7-9 leading to IL-6 suppression, modulation of immune function, and direct inhibition of cancer cell signaling pathways. Discover how this drug, originally designed to inhibit opioid receptors for treating addiction, has shown promising results for patients with chronic inflammatory and autoimmune conditions, with anecdotal reports of cancer resolution. Explore the growing clinical evidence supporting LDN's use in oncology, especially when combined with certain chemotherapy treatments. The presentation references multiple research papers and the LDN Research Trust website as resources for further information on this potentially groundbreaking approach to cancer management.
